Loading
Life sciences · Journal article
Journal of Clinical Medicine · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: 177Lu-PSMA-617 is an established standard-of-care treatment for eligible patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Treatment schedules and follow-up in routine practice may differ from clinical trial protocols. Post-approval evaluation is needed to determine whether trial-reported prostate-specific antigen (PSA) responses and adverse events are also observed outside trials. We assessed outcomes in heavily pretreated patients receiving 177Lu-PSMA-617. Methods: This retrospective study included 13 patients treated outside clinical trials at Severance Hospital, with follow-up through 30 June 2026. PSA50 and PSA90 denoted unconfirmed reductions of at least 50% and 90% from pretreatment baseline. Study-defined progression-free survival (PFS) included radiographic progression, a PSA increase of at least 50% from baseline considered disease progression, or death. Results: Median age was 69 years. All patients had received androgen-deprivation therapy, an androgen receptor pathway inhibitor, and docetaxel. Median baseline PSA was 88.79 ng/mL, and the median number of cycles was four. PSA50 and PSA90 occurred in six (46.2%) and three (23.1%) patients, respectively. Eight patients had a PFS event; median study-defined PFS was 5.9 months (95% confidence interval (CI), 1.4 months to not estimable). Two patients required activity reduction for cytopenias. Dry mouth was recorded in five patients (38.5%). Conclusions: PSA responses in this cohort support the applicability of trial findings to routine care. Documented adverse events included recognized toxicities. The PSA-inclusive PFS endpoint differs from trial radiographic PFS. Small sample size, concomitant treatment, and retrospective ascertainment limit interpretation. Larger cohorts with standardized follow-up are needed to assess response durability.